| PENNSYLVANIA |
Location: Abington
Abington
Memorial Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Sondra B. Mabry
215-481-2402
Back
to Top |
Location: Allentown
Lehigh
Valley Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Deborah R. Kane
610-402-0581
deborah.kane@lvh.com
Back
to Top |
Location: Bethlehem
St. Luke's
Hospital and Health Network
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Kelly A. Filchner
610-954-3582
Back
to Top |
Location: Doylestown
Doylestown
Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Karen E. Quinlan
215-345-2866
Back
to Top |
Location: Jenkintown
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Anna Wilkening
215-884-1700
Back to Top |
Location: Jenkintown
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Marvin Kalafer
877-379-3718
Back
to Top |
Location: Norristown
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Julie Niness
610-270-9571
Back to Top |
Location: Philadelphia
University of Pennsylvania
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Monica Hann
215-349-5903
monica.han@uphs.upenn.edu
Gerri Anselmo
215-662-4377
gerri.anselmo@uphs.upenn.edu
Christopher Clark
Back
to Top |
Location: Philadelphia
University of Pennsylvania
Trial Title and Description: Depression in Alzheimer's Disease-
The purpose of this study is to learn whether
treating individuals with Alzheimer's disease and
depression with the anti-depressant medication
Sertraline (Zoloft) is helpful to people with
Alzheimer's disease and to their families and
caregivers.
Enrollment Status: Recruiting
Study Dates: Start: July 2004
Condition: Alzheimer's disease,
Depression
Age Eligibility: 18 and
above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase
2,3
Study Type: Interventional
Sponsor: National Institute of
Mental Health (NIMH)
Contact Information:
Suzanne DiFilippo
215-349-8228
difilipp@mail.med.upenn.edu
Trisha Stump
215-349-8227
tstump@mail.med.upenn.edu
Back
to Top |
Location: Philadelphia
Pennsylvania Hospital
Trial Title and Description: Enhancing Care Coordination: Hospital
to Home for Cognitively Impaired Older Adults and
Their Caregivers-
To compare across three hospital sites the effects
on health and cost outcomes observed by interventions,
each designed to enhance adaptation and improve
outcomes of hospitalized cognitively impaired elders
and their caregivers.
Enrollment Status: Recruiting
Study Dates: Start: February 2006
Expected Completion: August 2010
Condition: Dementia, Alzheimer's
disease, Delirium, Cognitive disorders, Lewy body
disease
Age Eligibility: 70 and
above
Gender Eligibility: Both
Enrollment Goal: 420
Clinical Identifier: NCT00294307
Study Phase: Phase 1,
2
Study Type: Interventional
Sponsor: University of
Pennsylvania
Contact Information:
Margaret Crowley
215-829-8716
crowleym@uphs.upenn.edu
Back
to Top |
Location: Philadelphia
Penn-Presbyterian Medical Center
Trial Title and Description: Enhancing Care Coordination: Hospital
to Home for Cognitively Impaired Older Adults and
Their Caregivers-
To compare across three hospital sites the effects
on health and cost outcomes observed by interventions,
each designed to enhance adaptation and improve
outcomes of hospitalized cognitively impaired elders
and their caregivers.
Enrollment Status: Recruiting
Study Dates: Start: February 2006
Expected Completion: August 2010
Condition: Dementia, Alzheimer's
disease, Delirium, Cognitive disorders, Lewy body
disease
Age Eligibility: 70 and
above
Gender Eligibility: Both
Enrollment Goal: 420
Clinical Identifier: NCT00294307
Study Phase: Phase 1,
2
Study Type: Interventional
Sponsor: University of
Pennsylvania
Contact Information:
Kathy Witta
215-662-8796
kathy.witta@uphs.edu
Back
to Top |
Location: Philadelphia
Hospital
of the University of Pennsylvania
Trial Title and Description: Enhancing Care Coordination: Hospital
to Home for Cognitively Impaired Older Adults and
Their Caregivers-
To compare across three hospital sites the effects
on health and cost outcomes observed by interventions,
each designed to enhance adaptation and improve
outcomes of hospitalized cognitively impaired elders
and their caregivers.
Enrollment Status: Recruiting
Study Dates: Start: February 2006
Expected Completion: August 2010
Condition: Dementia, Alzheimer's
disease, Delirium, Cognitive disorders, Lewy body
disease
Age Eligibility: 70 and
above
Gender Eligibility: Both
Enrollment Goal: 420
Clinical Identifier: NCT00294307
Study Phase: Phase 1,
2
Study Type: Interventional
Sponsor: University of
Pennsylvania
Contact Information:
Michelle Feil, MSN
215-615-3800
feilm@uphs.upenn.edu
Back
to Top |
Location: Philadelphia
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Joel Streim
877-379-3718
Carol Lippa
877-379-3718
Back
to Top |
Location: York
York Cancer
Center / Wellspan Health
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Cecil Runyons
859-257-1412 ext. 235
preadvise@lsu.uky.edu
Back
to Top |
| RHODE ISLAND |
Location: Providence
Rhode Island Hospital
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Michele Astphan
401-444-2484
mastphan@lifespan.org
For more information, visit www.gapstudy.com
Back to Top
|
Location: Providence
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Diane Monast
401-455-6403
Back to Top |
Location: Providence
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Stephen Salloway
877-379-3718
Back
to Top |
| SOUTH CAROLINA |
Location: N. Charleston
Medical University of South Carolina
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Arthur Williams
843-740-1592, ext 17
alwpoe@musc.edu
For more information, visit www.gapstudy.com
Back to Top |
Location: North
Charleston
Medical University of South Carolina
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine
the safety and effectiveness of two anti-oxidant
treatment regimens in patients with mild to moderate
Alzheimer's disease. The anti-oxidant treatments
include vitamin E + C + alpha-lipoic acid, and
Coenzyme Q (CoQ).
Enrollment Status: Recruiting
Study Dates: Start:
January 2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National
Institute on Aging (NIA)
Contact
Information:
Stephanie Kirbach
843-740-1592
kirbach@musc.edu
Andrew Larkin
larkina@musc.edu
Aljoeson Walker
Back
to Top
|
Location: North
Charleston
Medical University of South Carolina
Trial Title and Description: Depression in Alzheimer's Disease-
The purpose of this study is to learn whether
treating individuals with Alzheimer's disease and
depression with the anti-depressant medication
Sertraline (Zoloft) is helpful to people with
Alzheimer's disease and to their families and
caregivers.
Enrollment Status: Recruiting
Study Dates: Start: July 2004
Condition: Alzheimer's disease,
Depression
Age Eligibility: 18 and
above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2,
3
Study Type: Interventional
Sponsor: National Institute of
Mental Health (NIMH)
Contact Information:
Martie Hatchell
843-740-1592, ext.
20
hatchell@musc.edu
Marilyn Stuckey
843-740-1592, ext. 13
stuckeym@musc.edu
Back
to Top |
Location: North Charleston
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jacob Mintzer
877-379-3718
Back
to Top |
| SOUTH
DAKOTA |
Location: Sioux Falls
Sioux
Community Cancer Consortium
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Judy Norman
605-331-3257
cincod@cpc-clinics.com
Back
to Top |
| TENNESSEE |
Location: Cordova
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Lee Stein
877-379-3718
Back
to Top |
Location: Franklin
Psychiatric Consultants
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Jessica Hart
615-807-4023
jessica.hart@psysolutions.com
Back to Top
|
Location: Knoxville
Thompson
Cancer Survival Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Crystal M. Dugger
865-541-2421
Back
to Top |
Location: Memphis
Baptist
Memorial Hospital- Memphis
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Pat Gish
901-226-0033
Back
to Top |
Location: Memphis
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Kenneth Sakauye
877-379-3718
Back
to Top |
Location: Nashville
Meharry
Medical College
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
N/A
Back
to Top |
Location: Nashville
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Harry Gwirtsman
877-379-3718
Back
to Top |
Location: Nashville
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
William Petrie
877-379-3718
Back
to Top |
Location: Oak Ridge
Methodist
Regional Cancer Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Brenda S. Morris
865-481-1664
bmorris@covhlth.com
Back
to Top |
TEXAS |
Location: Austin
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Larisa Schertz, RN
512-407-8628
Back to Top |
Location: Austin
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jaron Winston
877-379-3718
Back
to Top |
Location: Dallas
University of Texas, Southwestern Medical Center
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Charlotte Isah
214-648-9310
charlotte.isah@utsouthwestern.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: Dallas
Methodist
Hospitals of Dallas
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Mary Padilla
214-947-3621
marypadilla@mhd.com
Back
to Top |
Location: DeSoto
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Raj Shiwach
877-379-3718
Back
to Top |
Location: Houston
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Aline Hittle
713-798-5325
Back to Top |
Location: Houston
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Rachelle Doody
877-379-3718
Back
to Top |
Location: San Antonio
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Teri-Lynn Fielder
210-614-7483 ext 210
Back to Top |
Location: San Antonio
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Innovative Clinical Trials
Dr. James Garrison / Elizabeth Hendrix
210-377-2873
www.KiokuStudy.com
Back to Top |
Location: San Antonio
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Thomas Weiss
877-379-3718
Donald Royall
Back
to Top |
Location: Temple
Scott &
White CCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Laresa A. Trusty
254-724-8384
ltrusty@swmail.sw.org
Back
to Top |
Location: Call for details
Trial Title and Description: Effect of Testosterone Therapy in Men
With Mild Alzheimer's Disease and Low Testosterone-
Treatment with testosterone can improve performance
on tests of spatial ability in men with low
testosterone levels and mild Alzheimer's disease.
Improved performance on these tests may mean an
improved ability to get around in one's environment
without getting lost or injured. This could have a
positive impact on both patients and those who care
for them. We will investigate what areas of the brain
are involved in these improvements in spatial ability.
This will be done using a PET scan, which creates a
3-dimensional image of the brain that can allow us to
see how the brain functions.
Enrollment Status: Recruiting
Study Dates: Start: April 2007
Expected Completion: December 2007
Condition: Alzheimer's
disease
Age Eligibility: 65 and
above
Gender Eligibility: Male
Enrollment Goal: 12
Clinical Identifier: NCT00392912
Study Phase: N/A
Study Type: Interventional
Sponsor: VA Medical Center, Solvay
Pharmaceuticals
Contact Information:
Robert S. Tan
713-794-7382
Robert.Tan@med.va.gov
Maurita Carrejo
713-794-8766
Maurita.Carrejo@med.va.gov
Back
to Top |
| UNITED STATES |
Location: United States
Trial Title and Description: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy And Safety Of Eighteen Months of Treatment with PF-04494700 in Participants with Mild-To-Moderate Alzheimer’s disease
Much evidence suggests that Alzheimer‘s disease (AD) is caused by amyloid plaque deposits and tangles in the brain which lead to cognitive decline, memory loss and behavioral changes. Amyloid, one of the main components of plaques in AD, is known to bind to Receptors for Advanced Glycated Endproducts (or RAGE, for short) on the surface of cells (e.g. the brain’s nerve cells and microglial cells) and at the blood brain barrier. This binding may trigger inflammation and damage to nerve cells. However, by blocking amyloid-RAGE binding, researchers have found that plaque formation was reduced in animal models.
An experimental drug was developed as a RAGE antagonist, a novel pathway for trying to treat AD. The drug has been tested in laboratory animals, in small Phase I safety studies in healthy volunteers, and in a preliminary short safety study in AD patients. It is now being investigated in this larger Phase II clinical study to determine its efficacy (e.g. if it will slow the progressive decline associated with AD).
Enrollment Status: Currently enrolling
Study Dates: December 2007
Expected Completion for Enrollment: 2009
Condition: Probable mild to moderate Alzheimer’s disease
Age Eligibility: Age 50 and older
Gender Eligibility: Male or female
Enrollment Goal: 399
Clinical Identifier: NCT00566397
Study Phase: II
Study Type: Treatment
Sponsor: Industry-sponsored
Contact Information:
Name ADEAR
Phone 1-800- 438-4380
adear@nia.nih.gov
http://www.nia.nih.gov/Alzheimers/ResearchInformation/ClinicalTrials/RAGE.htm
|
UTAH |
Location: Salt Lake City
University of Utah Center for Alzheimer’s Care, Imaging and Research
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Courtney Montgomery
801-587-8385
courtney.montgomery@hsc.utah.edu
Back to Top |
Location: South
OgdenGSK Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in
clinical studies and is approved by the FDA as a
treatment for type II diabetes mellitus, a disease
that occurs when the body is unable to effectively use
glucose. RSG XR, the investigational drug used in this
study, is an extended-release form of RSG. This study
tests whether RSG XR safely provides clinical benefit
to people with mild to moderate Alzheimer’s disease
(AD) when combined with one of the currently approved
AD medications, Aricept®, Razadyne® or Exelon®. RSG XR
is a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start:
July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact
Information:
Navin
Varma
877-379-3718
Back
to Top
|
Location: Call for
details
Trial Title and Description: Exercise Treatment of Mild-Stage
Probable Alzheimer's Disease-
The purpose of this study is to
determine if participation in an exercise program
helps memory loss from getting worse, and if it
improves daily functioning and attitudes of those with
probable Alzheimer's disease. It involves
participation of both the person with memory loss and
someone who knows their daily activities (e.g.,
spouse, adult child, or
caregiver).
Enrollment Status: Recruiting
Study Dates: Start:
October 2006 Expected completion: July 2008
Condition: Alzheimer's
disease, Dementia
Age Eligibility: 65-89
Gender Eligibility: Both
Enrollment Goal: 79
Clinical Identifier: NCT00403507
Study Phase: Phase
2
Study Type: Interventional
Sponsor: Intermountain
Health Care, Inc., Deseret Foundation
Contact
Information:
Kelly
Garrett
801-408-5498
KellyDavisGarrett@intermountianmail.org
Cherie P. Brunker
801-408-8600
Back
to Top
|
| VERMONT |
Location: Bennington
GSK Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in
clinical studies and is approved by the FDA as a
treatment for type II diabetes mellitus, a disease
that occurs when the body is unable to effectively use
glucose. RSG XR, the investigational drug used in this
study, is an extended-release form of RSG. This study
tests whether RSG XR safely provides clinical benefit
to people with mild to moderate Alzheimer’s disease
(AD) when combined with one of the currently approved
AD medications, Aricept®, Razadyne® or Exelon®. RSG XR
is a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start:
July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact
Information:
Lisa
Catapano-Friedman
877-379-3718
Back
to Top
|
| VIRGINIA |
Location: Alexandria
GSK Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in
clinical studies and is approved by the FDA as a
treatment for type II diabetes mellitus, a disease
that occurs when the body is unable to effectively use
glucose. RSG XR, the investigational drug used in this
study, is an extended-release form of RSG. This study
tests whether RSG XR safely provides clinical benefit
to people with mild to moderate Alzheimer’s disease
(AD). RSG XR is a new approach to AD therapy and this
study tests a new way to treat AD by testing whether
one’s genetic makeup affects the response to the study
drug.
Enrollment Status: Not
yet recruiting
Study Dates: Start:
January 2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact
Information:
Stuart
Stark
877-379-3718
Back
to Top
|
Location: Charlottesville
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Paula Damgaard, RN, CCRC, GNS
434-243-5420
Back to Top |
| WASHINGTON |
Location: Bellingham
Cascadia Clinical Trials at St. Joseph
Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by
Vitamin E and Selenium (PREADVISE) prevention trial is
an important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May
2002 Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National
Institute on Aging (NIA), National Cancer Institute
(NCI)
Contact
Information:
Lorina
Hall
360-738-6756
Back
to Top
|
Location: Seattle
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Anita Ranta
206-277-2339
Back to Top |
Location: Seattle
University of
Washington
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Elaine Peskind
800-317-5382
Back
to Top |
Location: Seattle
Northwest Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Jennifer Armstrong
206-368-6599
Back
to Top |
Location: Seattle
Swedish
Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Jackie Dahlgren
206-215-3245
Back
to Top |
Location: Seattle
Virginia
Mason CCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Beth Edelheit
206-341-0446
beth.edelheit@vmmc.org
Back
to Top |
Location: Call for details
Trial Title and Description: Using Behavioral Programs to Treat
Sleep Problems in Individuals With Alzheimer's
Disease-
This study will compare four different behavioral
treatment programs to determine which is most
effective in reducing night-time disturbances in
individuals with Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: September
2005
Condition: Alzheimer's disease,
Sleep initiation and maintenance
disorders
Age Eligibility: 55 and
above
Gender Eligibility: Both
Enrollment Goal: 136
Clinical Identifier: NCT00183378
Study Phase: N/A
Study Type: Interventional
Sponsor: National Institute of
Mental Health
Contact Information:
Amy Moore
206-616-5550
amoore@u.washington.edu
Back
to Top |
| WISCONSIN |
Location: Madison
University of Wisconsin
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Maia Wroblewski
608-256-1901, ext 11514
mkwrob@medicine.wisc.edu
Back to Top |
Location: Marshfield
Marshfield
Clinic
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Debbie Schillinger
715-387-9521
schillid@mmrfmfldclin.edu
Back
to Top |
Location: Middleton
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Patrice Mockrud
608-827-2353
Back to Top |
Location: Milwaukee
Sinai
Samaritan Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Nancy Briggs
414-219-7370
nancy_brriggs@aurorra.org
Back
to Top |
Location: Waukesha
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Independent Psychiatric Consultants
Anne or Nancy
262-513-0700
www.KiokuStudy.com
Back to Top |
